Skip to main content

Table 2 Demographic data and baseline characteristics of the patients

From: A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

Characteristics Placebo (n = 23) 100 mg/day 5-Loxin® (n = 24) 250 mg/day 5-Loxin® (n = 23)
Sex (male/female; n) 5/18 7/17 8/15
Age (years) 52.43 ± 9.65 52.37 ± 8.37 53.22 ± 8.73
Body weight (kg) 61.48 ± 10.69 61.08 ± 10.67 54.84 ± 10.19
Body mass index (kg/m2) 26.05 ± 4.29 25.91 ± 4.94 22.64 ± 4.07
Visual analog score (mm) 56.88 ± 12.04 57.05 ± 8.71 55.62 ± 9.26
Lequesne's Functional Index 12.76 ± 2.6 12.1 ± 2.76 12.04 ± 3.03
WOMAC score    
   Pain subscale 38.04 ± 9.7 48.08 ± 14.05 37.17 ± 13.8
   Stiffness subscale 33.15 ± 13.3 31.8 ± 17.6 27.7 ± 16.8
   Function subscale 41.3 ± 9.6 41.5 ± 11.1 38.6 ± 11.1
  1. Values are expressed as mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.